Full Text View
Tabular View
No Study Results Posted
Related Studies
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia
This study is ongoing, but not recruiting participants.
First Received: October 11, 2001   Last Updated: February 6, 2009   History of Changes
Sponsor: III. Medizinische Klinik Mannheim
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00025402
  Purpose

RATIONALE: Giving chemotherapy, such as hydroxyurea, cytarabine, idarubicin, and etoposide before a donor bone marrow transplant or stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. Interferon alfa may interfere with the growth of cancer cells and slow the growth of cancer. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. It is not yet known whether chemotherapy is more effective with or without interferon alfa and/or bone marrow or stem cell transplant in treating patients with chronic myelogenous leukemia.

PURPOSE: This randomized phase III trial is studying chemotherapy and biological therapy to see how well it works compared with chemotherapy, biological therapy, and donor bone marrow transplant or autologous stem cell transplant in treating patients with chronic phase chronic myelogenous leukemia.


Condition Intervention Phase
Leukemia
Biological: filgrastim
Biological: recombinant interferon alfa
Drug: busulfan
Drug: cyclophosphamide
Drug: cytarabine
Drug: etoposide
Drug: hydroxyurea
Drug: idarubicin
Procedure: allogeneic bone marrow transplantation
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Active Control
Official Title: Randomized Multicenter Treatment Optimization Study In Chronic Myeloid Leukemia (CML) Interferon-a Vs. Allogeneic Stem Cell Transplantation Vs. High-Dose Chemotherapy Followed By Autografting And Interferon-a Maintainance In Early Chronic Phase

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Survival [ Designated as safety issue: No ]
  • Frequency, time-point, and duration of hematologic and cytogenetic remissions and of Philadelphia chromosome-negative and/or BCL-ABL-positive cells [ Designated as safety issue: No ]
  • Correlation of quality of hematological and cytogenetic remission with survival time [ Designated as safety issue: No ]
  • Course of the terminal phase [ Designated as safety issue: No ]
  • Toxicity [ Designated as safety issue: Yes ]
  • Effect of prognostic criteria and normal or subnormal WBC on chronic phase duration and survival time [ Designated as safety issue: No ]
  • Effect of early vs late high-dose therapy and autografting on feasibility, toxicity and survival times [ Designated as safety issue: Yes ]

Estimated Enrollment: 1000
Study Start Date: July 1997
Detailed Description:

OBJECTIVES:

  • Compare survival in patients with chronic myelogenous leukemia in early chronic phase treated with allogeneic bone marrow transplantation vs drug treatment with or without autologous peripheral blood stem cell transplantation.
  • Compare survival of patients with late-phase disease treated with high-dose cytarabine vs low-dose cytarabine followed by autografting and interferon alfa maintenance.
  • Compare survival of patients not responding cytogenetically to treatment with continued interferon alfa vs hydroxyurea.
  • Determine frequency, time-point, and duration of hematological and cytogenetic remissions and of Philadelphia chromosome-negative and/or BCR-ABL-positive cells on the various treatments.
  • Correlate the quality of hematological and cytogenetic remissions with survival time in patients treated with these regimens.
  • Compare the course of the terminal phase in patients treated with these regimens.
  • Compare the toxic effects of these regimens in these patients.
  • Determine the effect of prognostic criteria and normal or subnormal WBC on chronic phase duration and survival time in patients treated with these regimens.
  • Compare the effect of early vs late high-dose therapy plus autografting on feasibility, toxicity, and survival times in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to eligibility for transplantation (yes vs no).

All patients undergo cytoreduction comprising hydroxyurea (HU) IV daily.

Patients who are ineligible for or refuse transplantation are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive interferon alfa (IFN) subcutaneously (SC) daily. After 2 weeks of IFN therapy, patients also receive low-dose cytarabine (ARA-C) SC once daily for 10-15 days each month. Patients who do not achieve cytogenetic remission within 12 months continue to receive HU.
  • Arm II: Patients receive IFN SC daily. After 2 weeks of IFN therapy, patients also receive low-dose ARA-C SC daily for 10-15 days each month. Patients who do not achieve cytogenetic remission within 12 months continue to receive IFN therapy SC daily.

Patients who are eligible for transplantation with a related donor undergo allogeneic bone marrow transplantation. Patients may receive HU or IFN prior to transplantation. Patients may also receive oral high-dose busulfan daily for 4 days with or without cyclophosphamide or cyclophosphamide with total body irradiation.

Patients who are eligible for transplantation but do not have a related donor undergo peripheral blood stem cell (PBSC) harvest and are randomized to 1 of 2 treatment arms.

  • Arm III: Patients receive IFN and low-dose ARA-C as in arm I. Patients who accelerate on treatment may undergo autologous PBSC transplantation.
  • Arm IV: Patients receive idarubicin IV, ARA-C IV over 2 hours, and etoposide IV on days 1-3. Patients then undergo leukapheresis. Beginning on day 8, patients receive filgrastim (G-CSF) SC daily until end of leukapheresis. Patients then receive oral high-dose busulfan daily for 4 consecutive days. The following day, patients undergo reinfusion of autologous PBSC. After blood count recovery, patients receive maintenance IFN 3 times weekly for 8 weeks and then daily.

Patients are followed every 3 months for 3 years and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 1,000 patients will be accrued for this study within 5 years.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of chronic myelogenous leukemia in chronic phase

    • Previously untreated
  • Patients negative for Philadelphia chromosome and BCR-ABL translocation must fulfill at least 1 of the following criteria:

    • Impaired health status with reduced exercise tolerance
    • Spleen-related symptoms in cases of splenomegaly
    • Weight loss greater than 10% in 6 months
    • Fever greater than 38.5 degrees C on 5 consecutive days
    • Clinically relevant bone pain
    • Leukocytosis greater than 5,000/mm^3
    • Thrombocytosis greater than 100,000/mm^3

PATIENT CHARACTERISTICS:

Age:

  • Any age

Performance status:

  • Not specified

Life expectancy:

  • Not specified

Hematopoietic:

  • See Disease Characteristics

Hepatic:

  • Not specified

Renal:

  • Not specified

Other:

  • No other concurrent malignancy that is likely to require treatment during study or that is likely to reduce life expectancy
  • No severe concurrent disease or other cause that would preclude study
  • Not pregnant

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No prior interferon

Chemotherapy:

  • No prior chemotherapy

Endocrine therapy:

  • Not specified

Radiotherapy:

  • No prior radiotherapy

Surgery:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00025402

  Hide Study Locations
Locations
Czech Republic
Masaryk University Hospital
Brno, Czech Republic, 62500
Germany
Allgemeines Krankenhaus Altona
Hamburg, Germany, 22763
Allgemeines Krankenhaus Hagen
Hagen, Germany, D-58095
Asklepios Klinik Barmbek
Hamburg, Germany, D-22291
Bundeswehr Krakenhaus
Ulm, Germany, D-89070
Caritas - Krakenhaus Lebach
Lebach, Germany, 66822
Caritasklinik St. Theresia
Saarbrucken, Germany, D-66113
Charite - Campus Charite Mitte
Berlin, Germany, D-10117
Charite - Campus Virchow Klinikum
Berlin, Germany, D-13353
Clinic for Bone Marrow Transplantation and Hematology and Oncology
Idar-Oberstein, Germany, D-55743
Deutsche Klinik fuer Diagnostik
Wiesbaden, Germany, D-65191
Diakonie Klinikum Stuttgart
Stuttgart, Germany, D-70176
Diakonissen - Krankenhaus
Karlsruhe-Rueppur, Germany, 76199
DR Herbert - Nieper Krankenhaus Goslar
Goslar, Germany, 38642
Europahochhaus
Bochum, Germany, 44787
Evangelische Krankenhaus Hamm
Hamm, Germany, D-59063
Evangelisches Krankenhaus Essen Werden
Essen, Germany, D-45239
Franziskus Hospital
Bietigheim, Germany, 74321
Gemeinschaftspraxis Brunoehler
Karlsruhe, Germany, 76135
Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie
Ansbach, Germany, 91522
Gemeinschaftspraxis Fuer Innere Medizin, Hematologie Und Onkologie
Giessen, Germany, 35392
Gemeinschaftspraxis
Munich, Germany, 80331
Gemeinschaftspraxis
Niddatel-IIbenstadt, Germany, 61194
Gemeinschaftspraxis
Mannheim, Germany, D-68161
Gemeinschaftspraxis
Nuernberg, Germany, D-90402
Haematologie Und Internistische Onkologie
Hanau, Germany, 63450
Haematologisch Onkologische Praxis
Aachen, Germany, D-52070
Haematologische / Onkologische Schwerpunktpraxis
Krefeld, Germany, 47798
Haematologische Praxis
Augsburg, Germany, 86150
Haematologische Praxis
Stuttgart, Germany, D-70173
Haematologisch-Onkologische Praxis Altona
Hamburg, Germany, D-22767
Haematologisch-Onkologische Schwerpunktpraxis
Berlin, Germany, 13357
Hans - Susemihl - Krankenhaus
Emden, Germany, 26721
Helios Kliniken Wuppertal University Hospital
Wuppertal, Germany, D-42283
Helios Klinikum Berlin
Berlin, Germany, 13125
Hematologische Onkologische Praxis
Regensburg, Germany, 93047
Hematologische Praxis
Oldenburg, Germany, 26121
Hermann - Holthusen Institute for Radiotherapy
Hamburg, Germany, D-20099
II Medizinische Klinik - Klinikum Fuerth
Fuerth, Germany, D-90766
II. Medizinische Klinik
Aschaffenburg, Germany, RG 63739
III Medizinische Klinik Mannheim
Mannheim, Germany, D-68305
Internistiche Praxis
Erfurt, Germany, 99084
Jakobi Krankenhaus
Rheine, Germany, 48431
Kinderklinik - Universitaetsklinikum Aachen
Aachen, Germany, D-52074
Kinderklinik der Freier Universitaet Berlin
Berlin, Germany, D-14059
Klinik fuer Onkologie - Katharinenhospital Stuttgart
Stuttgart, Germany, D-70174
Klinik fuer Radioonkologie und Strahlentherapie
Goeppingen, Germany, 73035
Kreiskrankenhaus
Bad Hersfeld, Germany, 36251
Klinik und Poliklinik fuer Kinder und Jugendmedizin - Universitaetsklinikum Muenster
Muenster, Germany, D-48129
Klinik und Poliklinik fuer Urologie und Kinderurologie
Giessen, Germany, D-35392
Kliniken St. Antonius
Wuppertal 2, Germany, D-42283
Klinikum Augsburg
Augsburg, Germany, DOH-86156
Klinikum Bremen-Mitte
Bremen, Germany, D-28205
Klinikum Coburg
Coburg, Germany, 96450
Klinikum der Friedrich-Schiller Universitaet Jena
Jena, Germany, D-07740
Klinikum Der Hansestadt Stralsund - Klin. West
Stralsund, Germany, D-18410
Klinikum der J.W. Goethe Universitaet
Frankfurt, Germany, D-60590
Klinikum der Stadt Ludwigshafen am Rhein
Ludwigshafen am Rhein, Germany, D-67063
Klinikum Der Stadt Villingen - Schwenningen
Villingen-Schwenningen, Germany, D-78054
Klinikum der Universitaet Muenchen - Grosshadern Campus
Munich, Germany, D-81377
Klinikum der Universitaet Regensburg
Regensburg, Germany, D-93053
Klinikum Erfurt
Erfurt, Germany, 99089
Klinikum Garmisch - Partenkirchen GmbH
Garmisch-Partenkirchen, Germany, D-82467
Klinikum Herford
Herford, Germany, D-32049
Klinikum Kassel
Kassel, Germany, D-34125
Klinikum Kempten Oberallgaeu
Kempten, Germany, D-87439
Klinikum Krefeld GmbH
Krefeld, Germany, D-47805
Klinikum Lippe - Lemgo
Lemgo, Germany, D-32657
Klinikum Minden
Minden, Germany, D-32423
Klinikum Nuernberg - Klinikum Nord
Nuernberg, Germany, D-90419
Klinikum Nuernberg - Klinikum Sued
Nuernberg, Germany, D-90471
Klinikum Oldenburg
Oldenburg, Germany, D-26133
Klinikum Rechts Der Isar - Technische Universitaet Muenchen
Munich, Germany, D-81675
Klinikum Remscheid GmbH
Remscheid, Germany, D-42859
Klinikum St. Marien
Amberg, Germany, D-92224
Krankenanstalt Mutterhaus der Borromaerinnen
Trier, Germany, D-54219
Krankenhaus Barmherzige Brueder Regensburg
Regensburg, Germany, D-93049
Krankenhaus Bietigheim
Bietigheim, Germany, 74321
Krankenhaus Dueren
Dueren, Germany, 52351
Krankenhaus Hohe Warte Mediziniche Klinik
Bayreuth, Germany, 95445
Krankenhaus Maria Hilf GmbH
Moenchengladbach, Germany, DOH-41063
Krankenhaus Muenchen Neuperlach
Munich, Germany, D-81737
Krankenhaus Muenchen Schwabing
Munich, Germany, 80804
Krankenhaus Neukoelln
Berlin, Germany, D-12313
Krankenhaus Siloah - Medizinische Klinik II
Hannover, Germany, D-30449
Krankenhaus St. Michael
Voeklingen, Germany, 66333
Kreiskrankenhaus Boeblingen
Boeblingen, Germany, 71032
Kreiskrankenhaus Fuessen
Fuessen, Germany, 87629
Kreiskrankenhaus Mellrichstadt
Mellrichstad, Germany, DT-97638
Kreiskrankenhaus Radebeul
Radebeul, Germany, D-01445
Kreiskrankenhaus Siegen
Siegen, Germany, D-57076
Kreiskrankenhaus
Waldroel, Germany, 51545
Kreiskrankenhaus
Aalen, Germany, 73430
Klinik Konstanz
Konstanz, Germany, 78461
Luisenkrankenhaus
Lindenfels, Germany, 64678
Malteser Krankenhaus
Flensburg, Germany, D-24939
Marienhospital Bottrop gGmbH
Bottrop, Germany, D-46236
Medizinische Hochschule Hannover
Hannover, Germany, D-30625
Medizinische Kl. Klinikum Innenstadt Universitaet Muenchen
Munich, Germany, D-80336
Medizinische Klinik Am Lukas - Krankenhaus
Buende, Germany, 32257
Medizinische Klinik I
Dresden, Germany, D-01307
Medizinische Klinik III - Universitaetsklinikum Erlangen
Erlangen, Germany, D-91054
Medizinische Poliklinik
Bonn, Germany, D-53111
Medizinische Universitaetsklinik I at the University of Cologne
Cologne, Germany
Medizinische Universitaetsklinik und Poliklinik
Heidelberg, Germany, 69115
Michael Schaefers und Partner
Duisburg, Germany, D-47051
Onkolog - Haematolog Schwerpunktpraxis
Berlin, Germany, D-10559
Onkolog Gemeinschaftspraxis
Frankfurt, Germany, 60389
Onkologische Schwerpunkt Praxis
Erlangen, Germany, D-91052
Onkologische Schwerpunktpraxis - Leer
Leer, Germany, D-26789
Onkologische Schwerpunktpraxis Bielefeld
Bielefeld, Germany, D-33602
Onkologische Schwerpunktpraxis Lueneburg
Lueneburg, Germany, D-21391
Onkologische Schwerpunktpraxis
Cottbus, Germany, D-03046
Onkologischer Schwerpunkt Lerchenfeld
Hamburg, Germany, D-22081
Paracelsus - Klinik Osnabrueck
Osnabrueck, Germany, D-49076
Philipps-Universitaet Marburg Klinikum
Marburg, Germany, D-35033
Praxis am Evangelischen Krankenhaus Bethanien
Iserlohn, Germany, D-58644
Praxis DR. J. Weniger
Erfurt, Germany, D-99085
St. Marien - Krankenhaus Siegen GMBH
Siegen, Germany, D-57072
Praxis fuer Haematologie und Interne Onkologie
Norderstedt, Germany, 22844
Praxis Fuer Haematologie/Onkologie
Luebeck, Germany, D-23560
Praxis Fuer Haemotologie Und Internistischer Onkologie
Wuppertal, Germany, 42105
Praxis fuer Innere Medizin und Haematologie
Munich, Germany, D-80797
Praxis Fuer Internistische Haematologie / Onkologie
Troisdorf, Germany, 53840
Praxis Gemeinschaft
Cologne, Germany, D-50676
Prosper-Hospital Recklinghausen
Recklinghausen, Germany, D-45659
Trier, Germany, D-54290
Robert-Bosch-Krankenhaus
Stuttgart, Germany, 70376
Ruppiner Klinikum GMBH
Neuruppin, Germany, 16816
Saechsische Schweiz Klinik
Sebnitz, Germany, D-01855
Schwerpunktpraxis fuer Haematologie und Onkologie
Saarbruecken, Germany, D-66113
Schwerpunktpraxis für Rheumatologie und Haematologie/Internistische Onkologie
Tuebingen, Germany, D-72072
Southwest German Cancer Center at Eberhard-Karls-University
Tuebingen, Germany, D-72076
St Marienkrankenhaus
Ludwigshafen, Rhein, Germany, D-67067
St. Antonius Hospital
Eschweiler, Germany, DOH-52249
St. Elisabeth Krankenhaus
Ravensburg, Germany, 88212
St. Hedwig Kranken Haus
Berlin, Germany, 10115
St. Irmgardis Krankenhaus
Viersen-Suechteln, Germany, 41749
St. Johannes Hospital - Medical Klinik II
Duisburg, Germany, D-47166
St. Joseph Hospital
Bremerhaven, Germany, D-27568
Praxis Fuer Haematologie Internistische Onkologie
Cologne, Germany, D-50677
St. Marien Hospital - Katholisches Krankenhaus Hagen gGmbH
Hagen, Germany, D-58095
St. Marien-Hospital Hamm - Klinik Knappenstrasse
Hamm, Germany, D-59071
St. Vincentius-Kliniken
Karlsruhe, Germany, D-76137
St. Willehad Hospital
Wilhelmshaven, Germany, D-26382
Stadt. KH Dresden - Neustadt
Dresden, Germany, 01129
Staedt Krankenhaus
Sebnitz, Germany, D-01855
Staedtisches Klinikum Braunschweig
Braunschweig, Germany, D-38114
Staedtisches Klinikum Karlsruhe gGmbH
Karlsruhe, Germany, 76133
Staedtisches Krankenhaus Muenchen - Harlaching
Munich, Germany, D-81545
Staedtisches Krankenhaus
Pforzheim, Germany, 75175
Tumorzentrum Berlin-Moabit
Berlin, Germany, 10967
Universitaets - Kinderpoliklinik
Muenchen, Germany, 80336
Munich, Germany, 80637
Universitaetsklinikum des Saarlandes
Homburg, Germany, 66424
Universitaetsklinikum Duesseldorf
Duesseldorf, Germany, D-40225
Universitaetsklinikum Essen
Essen, Germany, D-45122
Universitaetsklinikum Freiburg
Freiburg, Germany, D-79106
Universitaetsklinikum Goettingen
Goettingen, Germany, D-37075
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany, D-20246
Universitaetsklinikum Ulm
Ulm, Germany, D-89081
University Hospital Schleswig-Holstein - Kiel Campus
Kiel, Germany, D-24105
Urologische Klinik - Universitaetsklinikum Aachen
Aachen, Germany, D-52074
Vinzentiuskrankenhaus
Landau, Germany, D-76829
Universitaetsklinikum Bonn
Bonn, Germany, D-53105
Wenckebach - Krankenhaus
Berlin, Germany, 12099
Munich, Germany, D-81241
Zentralkrankenhaus
Bremerhaven, Germany, N 27574
Poland
Medical University of Gdansk
Gdansk, Poland, 80-211
Silesian Medical Academy
Katowice, Poland, 40-029
Spain
Hospital Universitario Virgen de la Victoria
Malaga, Spain, 29010
Switzerland
Bezirksspital Dornach
Dornach, Switzerland, CH-4143
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland, CH-1011
Facharzt FMH Fuer Innere Medizin and Oncology
Baar, Switzerland, CH-6340
Facharzt Fuer Onkologie-Hematologie
Bern, Switzerland, 3013
FMH f. Innere Medizin and Hematologie
Grosshochstetten, Switzerland, 3506
Hopital Cantonal Universitaire de Geneve
Geneva, Switzerland, CH-1211
Basel, Switzerland, CH 4051
Inselspital Bern
Bern, Switzerland, CH-3010
Institut Central des Hopitaux Valaisans
Sion, Switzerland, CH-1951
Kantonspital Aarau
Aarau, Switzerland, CH-5001
Kantonsspital - St. Gallen
St. Gallen, Switzerland, CH-9007
Kantonsspital, Luzerne
Luzerne, Switzerland, CH-6016
Klinik Hirslanden
Zurich, Switzerland, CH-8008
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland, CH-6500
UniversitaetsSpital Zuerich
Zurich, Switzerland, CH-8091
Universitaetsspital-Basel
Basel, Switzerland, CH-4031
Inneremedizin FMH
Breitenbach, Switzerland, 4226
Sponsors and Collaborators
III. Medizinische Klinik Mannheim
Investigators
Study Chair: Ruediger Hehlmann, MD III. Medizinische Klinik Mannheim
  More Information

Additional Information:
No publications provided

Study ID Numbers: CDR0000068957, III-MK-CML-3A, EU-20118
Study First Received: October 11, 2001
Last Updated: February 6, 2009
ClinicalTrials.gov Identifier: NCT00025402     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
chronic phase chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia
Philadelphia chromosome negative chronic myelogenous leukemia
childhood chronic myelogenous leukemia
atypical chronic myeloid leukemia

Additional relevant MeSH terms:
Antimetabolites
Anti-Infective Agents
Interferon Type I, Recombinant
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Antineoplastic Agents
Hydroxyurea
Hematologic Agents
Physiological Effects of Drugs
Cyclophosphamide
Antibiotics, Antineoplastic
Leukemia
Therapeutic Uses
Growth Inhibitors
Angiogenesis Modulating Agents
Alkylating Agents
Etoposide
Nucleic Acid Synthesis Inhibitors
Cytarabine
Interferon-alpha
Antisickling Agents
Neoplasms by Histologic Type
Hematologic Diseases
Growth Substances
Interferons
Myeloproliferative Disorders
Enzyme Inhibitors
Leukemia, Myeloid
Immunosuppressive Agents

ClinicalTrials.gov processed this record on November 27, 2009